{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:54:37Z","timestamp":1782755677263,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111681","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T06:02:13Z","timestamp":1708149733000},"page":"111681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR\/TIGIT pathway"],"prefix":"10.1016","volume":"130","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-ping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-8232","authenticated-orcid":false,"given":"Ren","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.intimp.2024.111681_b0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0015","first-page":"113","article-title":"The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review","volume":"7","author":"Pinter","year":"2021","journal-title":"J. Am. Med. Assoc.Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111681_b0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev.Clin Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111681_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jceh.2019.11.009","article-title":"Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab","volume":"10","author":"Amjad","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.intimp.2024.111681_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111681_b0035","first-page":"3582","article-title":"The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance","volume":"13","author":"Zhang","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.111681_b0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2024.111681_b0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.31394","article-title":"Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity","volume":"73","author":"Caruso","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.intimp.2024.111681_b0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7150\/jca.10398","article-title":"Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC","volume":"6","author":"Hiwatashi","year":"2015","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0070","doi-asserted-by":"crossref","first-page":"2215096","DOI":"10.1080\/2162402X.2023.2215096","article-title":"CD8 T cell-mediated depletion of HBV surface-antigen-expressing, bilineal-differentiated liver carcinoma cells generates highly aggressive escape variants","volume":"12","author":"Qiu","year":"2023","journal-title":"Oncoimmunology."},{"issue":"19","key":"10.1016\/j.intimp.2024.111681_b0075","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.7150\/jca.32985","article-title":"Regional biomechanical imaging of liver cancer cells","volume":"10","author":"Pei","year":"2019","journal-title":"J. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2024.111681_b0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.111681_b0085","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41575-018-0033-6","article-title":"Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research","volume":"15","author":"Brown","year":"2018","journal-title":"Nat. Rev. Gastroenterol Hepatol."},{"issue":"18","key":"10.1016\/j.intimp.2024.111681_b0090","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"issue":"10027","key":"10.1016\/j.intimp.2024.111681_b0095","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.intimp.2024.111681_b0100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12920-023-01614-8","article-title":"M7G methylated core genes (METTL1 and WDR4) and associated RNA risk signatures are associated with prognosis and immune escape in HCC","volume":"16","author":"Li","year":"2023","journal-title":"BMC Med. Genomics"},{"issue":"2","key":"10.1016\/j.intimp.2024.111681_b0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrgastro.2010.221","article-title":"Immunotherapy: Therapeutic potential of genetically modified HBV-specific T cells for chronic HBV infection and HBV-related HCC","volume":"8","author":"Wood","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10064","key":"10.1016\/j.intimp.2024.111681_b0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"10126","key":"10.1016\/j.intimp.2024.111681_b0120","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10088","key":"10.1016\/j.intimp.2024.111681_b0125","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.intimp.2024.111681_b0130","doi-asserted-by":"crossref","first-page":"e2107674","DOI":"10.1002\/adma.202107674","article-title":"Dual Tumor Microenvironment Remodeling by Glucose-Contained Radical Copolymer for MRI-Guided Photoimmunotherapy","volume":"34","author":"Cheng","year":"2022","journal-title":"Adv. Mater."},{"issue":"16","key":"10.1016\/j.intimp.2024.111681_b0135","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.scib.2022.07.018","article-title":"Antigen self-presenting nanovaccine for cancer immunotherapy","volume":"67","author":"Liang","year":"2022","journal-title":"Sci Bull (beijing)."},{"issue":"6","key":"10.1016\/j.intimp.2024.111681_b0140","article-title":"Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma","volume":"26","author":"Xu","year":"2023","journal-title":"Int. J. Pharm. x."},{"issue":"4","key":"10.1016\/j.intimp.2024.111681_b0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2024.111681_b0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.72.3.486","article-title":"Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells","volume":"72","author":"Imaizumi","year":"2002","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111681_b0155","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","article-title":"The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma","volume":"79","author":"Coca","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A","article-title":"Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy","volume":"83","author":"Taketomi","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2024.111681_b0165","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1067\/mtc.2001.113026","article-title":"The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma","volume":"121","author":"Takanami","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.intimp.2024.111681_b0170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V","article-title":"Prognostic value of intratumoral natural killer cells in gastric carcinoma","volume":"88","author":"Ishigami","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2024.111681_b0175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00262-004-0646-1","article-title":"Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas","volume":"54","author":"C\u00f3zar","year":"2005","journal-title":"CancerImmunol Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2024.111681_b0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00262-013-1511-x","article-title":"Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma","volume":"63","author":"Sznurkowski","year":"2014","journal-title":"CancerImmunol Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","article-title":"Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer","volume":"35","author":"Villegas","year":"2002","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111681_b0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.30347","article-title":"Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatology"},{"issue":"2020","key":"10.1016\/j.intimp.2024.111681_b0195","first-page":"6437057","article-title":"Research Progress on NK Cell Receptors and Their Signaling Pathways","volume":"24","author":"Chen","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"8","key":"10.1016\/j.intimp.2024.111681_b0200","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.111681_b0205","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2024.111681_b0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Xin","year":"2020","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:09:23Z","timestamp":1761588563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":42,"alternative-id":["S1567576924001991"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111681","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3430825\/v1","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR\/TIGIT pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111681"}}